

IMMUCELL CORP /DE/  
Form 8-K  
September 30, 2009

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

**Date of Report: September 30, 2009**  
**(Date of earliest event reported)**

**ImmuCell Corporation**  
**(Exact name of registrant as specified in its charter)**

**ME**

**(State or other jurisdiction  
of incorporation) 001-12934**

**(Commission File Number) 01-0382980**

**(IRS Employer  
Identification Number)**

**56 Evergreen Drive**

**(Address of principal executive offices) 04103**

**(Zip Code)**

**207-878-2770**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events**

ImmuCell Announces Initial Results from its pivotal effectiveness study of Mast Out(R).  
ImmuCell's Mastitis Drug Meets Pivotal Effectiveness Study End Point.

**Item 9.01. Financial Statements and Exhibits**

**(a) Financial statements:**

None

**(b) Pro forma financial information:**

None

**(c) Shell company transactions:**

None

**(d) Exhibits**

99.1 Press Release of ImmuCell Corporation dated September 30, 2009

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 30, 2009

**IMMUCELL CORPORATION**

By: /s/ Michael F. Brigham

Michael F. Brigham

*President and CEO*

---

**Exhibit Index** **Exhibit No.** **Description** 99.1 Press Release of ImmuCell Corporation dated September 30, 2009